跳至主要内容
临床试验/NCT01608555
NCT01608555已完成4 期

Tobramycin 300 mg o.d. Aerosol in in Adult Patients With Cystic Fibrosis: Pilot Study on Antimicrobial Activity

University of Milan1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2012年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
10
试验地点
1
主要终点
Evaluation of bacterial load decrease

研究概览

简要总结

The study will include 10 adult patients with cystic fibrosis. The aim of the study is to evaluate whether Tobramycin 300 mg aerosol once-a-day for 28 days can reduce the bacterial load in the airways. Secondary end-point is the evaluation of variation in bacterial susceptibility during and at the end of study period.

详细描述

Ten adult patients with cystic fibrosis will be enrolled in a stable phase and will received prophylaxis with aerosol of Tobramycin 300 mg once a day for 28 days.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients, male and female, age range 18-45 years
  • Diagnosis of cystic fibrosis
  • FEV1 >50% predicted.
  • sputum samples available
  • Chest x ray negative for pneumonia and tuberculosis
  • Informed consent

排除标准

  • Allergy to tobramycin
  • Use of systemic steroids in the previous 2 weeks
  • Pregnancy or breast feeding
  • Treatment with other experimental drug in the previous 3 months

研究组 & 干预措施

inhaled tobramycin once-a-day

Experimental

Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.

干预措施: tobramycin (Drug)

结局指标

主要结局

Evaluation of bacterial load decrease

时间窗: day 7-9 vs day 1, day 14-16 vs day 7-9, day 28-30 vs day 14-26

Bacterial load in sputum will be evaluated during and at the end of treatment

次要结局

  • Evaluation of inflammatory serum biomarker(day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16)
  • Evaluation of serum biomarker(day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16)
  • evaluation of serum biomarker(day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Francesco Blasi

Professor of respiratory medicine

University of Milan

研究点 (1)

Loading locations...

相似试验

Tobramycin 300 mg Once-a-day (o.d.) Aerosol in... | 临床试验